Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

TB-500 vs Glow

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Glow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

TB-500

Anecdotal + Animal Studies

Glow

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

TB-500 Glow
Class Thymosin β4 fragment; tissue repair Three-component regenerative blend (matrikine + cytoprotective + actin-regulator)
Drug class Tissue Repair Tissue Repair
Mechanism Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate.
Route SC / IM SC injection
Half-life Several hrs to days (tissue uptake) Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake)
Dosage (research) 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly Typical SC protocols deliver ~250-500 mcg per component daily for 4-6 week loading cycles. Confirm per-component dose from the vial total before reconstitution
Evidence tier Anecdotal + Animal Studies Anecdotal
Research depth 32 indexed (PubMed 19 · CT 1 · EPMC 12) —
Availability Compounding Restricted Compounding Restricted
Reported risks WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns No human trials of the combined formulation; TB-500 WADA-banned with theoretical pro-proliferative concerns; chronic GHK-Cu raises copper-accumulation considerations at high doses; injection-site reactions

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick TB-500 or Glow?

TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Glow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Glow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between TB-500 and Glow?

TB-500 is classed as Thymosin β4 fragment; tissue repair; Glow is classed as Three-component regenerative blend (matrikine + cytoprotective + actin-regulator). Reported mechanism: TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration; Glow, Layered remodelling: GHK-Cu's copper-peptide matrikine signal upregulates collagen and elastin transcription and engages roughly 4,000 wound-healing genes; BPC-157 drives angiogenesis via VEGFR2 and stabilises epithelial / connective-tissue repair; TB-500 sequesters G-actin to enable cell migration and amplifies stem-cell mobilisation. Together: matrix synthesis + vessel-bed repair + cell-migration substrate. Reported half-life: TB-500, Several hrs to days (tissue uptake); Glow, Composite: hours (BPC-157 / GHK-Cu) to days (TB-500 tissue uptake). Routes in published studies: TB-500, SC / IM; Glow, SC injection.

Which has stronger evidence, TB-500 or Glow?

TB-500 and Glow sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. TB-500 is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 32 indexed studies. Glow is graded Anecdotal, with 3 cited sources on its reference page.

Which is more accessible, TB-500 or Glow?

Neither TB-500 nor Glow is an FDA-approved drug. Catalog status: TB-500, Compounding Restricted; Glow, Compounding Restricted. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.

Are TB-500 and Glow ever combined?

TB-500 and Glow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…